HLX10+chemo

DRUG2 trials

Sponsors

Shanghai Henlius Biotech

Conditions

SCLC, Extensive StageSquamous Non-small-cell Lung Cancer

Phase 2

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Shanghai Henlius BiotechSquamous Non-small-cell Lung Cancer

Start: 2022-01-18End: 2024-10-30Target: 156Updated: 2022-05-06

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

Active, not recruitingNCT06812260

Shanghai Henlius BiotechSCLC, Extensive Stage

Start: 2025-06-24End: 2027-10-31Target: 26Updated: 2026-05-20

Related Papers

A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer.

Journal of Clinical Oncology2025-05-28